Literature DB >> 9695186

Positive and negative roles of the tyrosine kinase Lyn in B cell function.

A L DeFranco1, V W Chan, C A Lowell.   

Abstract

The function of Lyn in B cell activation has been studied recently by examining the properties of B cells from mice in which the lyn gene has been inactivated by gene targeting. These mice show evidence of B cell hyperreactivity in vivo, as the number of B lymphoblastoid cells greatly increase with age, IgM levels increase by 10-fold or more, and auto-antibodies to double-stranded DNA and other nuclear antigens become apparent. B cells from lyn -/- mice also exhibit enhanced BCR-induced activation of MAP kinases, intracellular calcium elevation and proliferative responses in vitro. These phenomena may relate to participation of Lyn in events that serve to decrease B cell responses to antigen. Among the leading candidates for these suppressive events are the inhibition of B cell antigen receptor function by Fc gamma RIIb1 and by CD22. Although Lyn also participates positively in the initial events of B cell antigen receptor signal transduction, this function can also be supplied by other tyrosine kinases, presumably other Src-family kinases. In contrast, some aspects of inhibition by CD22 appear to be almost completely dependent upon Lyn and Fc gamma RIIb1 inhibition is also diminished in the absence of Lyn. Thus, the net effect of Lyn action is negative rather than positive for B cell activation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9695186     DOI: 10.1006/smim.1998.0122

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  28 in total

1.  Essential role for the C-terminal noncatalytic region of SHIP in FcgammaRIIB1-mediated inhibitory signaling.

Authors:  M J Aman; S F Walk; M E March; H P Su; D J Carver; K S Ravichandran
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

2.  FcgammaRIIB signals inhibit BLyS signaling and BCR-mediated BLyS receptor up-regulation.

Authors:  Jenni E Crowley; Jason E Stadanlick; John C Cambier; Michael P Cancro
Journal:  Blood       Date:  2008-09-12       Impact factor: 22.113

Review 3.  Homeostasis and regulation of autoreactive B cells.

Authors:  Sujin Lee; Yeunjung Ko; Tae Jin Kim
Journal:  Cell Mol Immunol       Date:  2020-05-07       Impact factor: 11.530

Review 4.  Basophils and autoreactive IgE in the pathogenesis of systemic lupus erythematosus.

Authors:  Nicolas Charles; Juan Rivera
Journal:  Curr Allergy Asthma Rep       Date:  2011-10       Impact factor: 4.806

Review 5.  Multiple roles of Lyn kinase in myeloid cell signaling and function.

Authors:  Patrizia Scapini; Shalini Pereira; Hong Zhang; Clifford A Lowell
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

6.  Multi-transmembrane protein K15 of Kaposi's sarcoma-associated herpesvirus targets Lyn kinase in the membrane raft and induces NFAT/AP1 activities.

Authors:  Nam-Hyuk Cho; Young-Ki Choi; Joong-Kook Choi
Journal:  Exp Mol Med       Date:  2008-10-31       Impact factor: 8.718

7.  Autoimmunity risk alleles: hotspots in B cell regulatory signaling pathways.

Authors:  John C Cambier
Journal:  J Clin Invest       Date:  2013-04-24       Impact factor: 14.808

8.  Monovalent and multivalent ligation of the B cell receptor exhibit differential dependence upon Syk and Src family kinases.

Authors:  Sayak Mukherjee; Jing Zhu; Julie Zikherman; Ramya Parameswaran; Theresa A Kadlecek; Qi Wang; Byron Au-Yeung; Hidde Ploegh; John Kuriyan; Jayajit Das; Arthur Weiss
Journal:  Sci Signal       Date:  2013-01-01       Impact factor: 8.192

9.  MicroRNA 4323 induces human bladder smooth muscle cell proliferation under cyclic hydrodynamic pressure by activation of erk1/2 signaling pathway.

Authors:  Yi Sun; Deyi Luo; Yuchun Zhu; Kunjie Wang
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-04

10.  A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE.

Authors:  Matilda W Nicholas; Mary Anne Dooley; Susan L Hogan; Jennifer Anolik; John Looney; Ingnacio Sanz; Stephen H Clarke
Journal:  Clin Immunol       Date:  2008-02       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.